Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Treatment of Patients With Local Recurrence of Esophageal Cancer

NCT04390945 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Henan University of Science and Technology as lead sponsor.

NCT NCT04390945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04390945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Treatment of Patients With Local Recurrence of Esophageal Cancer
Lead sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2021
Completion date
August 31, 2024
Enrollment
62 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer